A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

Experts and guidelines recommend vesicular monoamine 2 transporter (VMAT2) inhibitors as the best option for treating more severe cases of tardive dyskinesia, an involuntary movement disorder caused ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...

Deep brain stimulation (DBS) may be helpful in severe cases of tardive dyskinesia that doesn’t respond to other treatments. Tardive dyskinesia (TD) causes involuntary movements of the tongue, neck, ...

AIMS exams should be routine, even when using telemedicine, experts say ...

People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

The FINANCIAL — Teva Pharmaceutical Industries Ltd. on November 9 announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to SD-809 ...

Prochlorperazine is used to treat severe nausea, vomiting, and schizophrenia. It can have serious side effects like sedation and movement disorders, including tardive dyskinesia. People with certain ...

Tardive dyskinesia (TD) is a condition that causes uncontrollable, repetitive movements in different parts of your body, such as your face, limbs, and torso. This neurological disorder not only ...

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...